Company Overview
Company Name
HEALIOS K.K.
Representative
Hardy TS Kagimoto, MD, Chairman and CEO
Establishment
February 24, 2011
Paid in Capital
1,678 million yen (As of Dec. 31, 2023)
Head Office
Hibiya Mitsui Tower 12F, WORK STYLING, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan
Number of Employees
61 (As of Dec. 31, 2023)
Business
Research, development and manufacturing of cell therapy/ regenerative medicine products
Research Institution
Kobe Research Institute
Affiliated Company
Sighregen Co., Ltd.
(Joint Venture with Sumitomo Pharma Co., Ltd.)
Subsidiaries
・Healios NA Inc.
（Established in February 2018）
・Saisei Ventures LLC
（Established in January 2021 as a venture fund investment advisor）
・Saisei Capital Ltd.
（Established in January 2021 as a venture fund general partner）
・Saisei Bioventures, L.P.
（Established in January 2021 as a venture fund limited partnership）
・ProcellCure Inc.（Established in July 2023 to promote development of ARDS）
・eNK Therapeutics Inc.（Established in August 2023 to promote R&D of eNK cells）
Access
Tokyo Office
Address
Hibiya Mitsui Tower 12F, WORK STYLING, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan
Chiyoda Line
Hibiya Line
Mita Line
Direct access from Hibiya Station (subway)
JR Yamanote Line
JR Keihin Tohoku Line
Yurakucho Line
5-minute walk from Yurakucho Station
Kobe Research Institute
Address
Kobe KIMEC Center Bldg. 3F 1-5-2 Minatojima-Minamimachi Chuo-ku, Kobe, Hyogo 650-0047
Port Liner Monorail
2-minute walk from Iryo Center Station